Seres Therapeutics, Inc.

NasdaqGS:MCRB 株式レポート

時価総額：US$139.4m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Seres Therapeutics マネジメント

マネジメント 基準チェック /34

Seres Therapeutics'の CEO はEric Shaffで、 Jan2019年に任命され、 の在任期間は 5.42年です。 の年間総報酬は$ 3.16Mで、 21.7%給与と78.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.093%を直接所有しており、その価値は$ 94.39K 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と7.8年です。

主要情報

Eric Shaff

最高経営責任者

US$3.2m

報酬総額

CEO給与比率21.7%
CEO在任期間5.7yrs
CEOの所有権0.1%
経営陣の平均在職期間5yrs
取締役会の平均在任期間8yrs

経営陣の近況

Recent updates

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 23

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Jul 13
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 44% But Investors Aren't Buying For Growth

Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

May 08
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Fly 46% But Investors Aren't Buying For Growth

Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Mar 23
Benign Growth For Seres Therapeutics, Inc. (NASDAQ:MCRB) Underpins Stock's 30% Plummet

Seres Therapeutics' Balancing Act: Breakthrough IP And Financing Concerns

Jan 30

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Dec 18
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 30% Price Drop

Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Aug 31
Lacklustre Performance Is Driving Seres Therapeutics, Inc.'s (NASDAQ:MCRB) 27% Price Drop

Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Aug 09
Seres Therapeutics (NASDAQ:MCRB) Has Debt But No Earnings; Should You Worry?

Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Dec 28
Is Seres Therapeutics (NASDAQ:MCRB) Weighed On By Its Debt Load?

Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Sep 01
Estimating The Fair Value Of Seres Therapeutics, Inc. (NASDAQ:MCRB)

Seres Therapeutics: What The Market Is Missing

Aug 19

Seres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22M

Aug 03

Seres Therapeutics: The Good And The Challenging

Jul 12

Seres Therapeutics stock slips on $100M stock offering

Jun 30

Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Jun 16
Is Seres Therapeutics (NASDAQ:MCRB) Using Too Much Debt?

Seres Therapeutics: As Biotech Fades The Case For Seres Investment Strengthens

Jun 09

Seres Therapeutics Is Playing A Long Game

Mar 06

Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 02
Some Seres Therapeutics, Inc. (NASDAQ:MCRB) Analysts Just Made A Major Cut To Next Year's Estimates

Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Dec 27
Rock star Growth Puts Seres Therapeutics (NASDAQ:MCRB) In A Position To Use Debt

Seres Therapeutics Molecular Data On SER-109 Looks Good

Oct 04

Seres Therapeutics: Here We Go Again

Sep 09

CEO報酬分析

Seres Therapeutics の収益と比較して、Eric Shaff の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2024n/an/a

-US$162m

Mar 31 2024n/an/a

-US$83m

Dec 31 2023US$3mUS$685k

-US$114m

Sep 30 2023n/an/a

-US$141m

Jun 30 2023n/an/a

-US$153m

Mar 31 2023n/an/a

-US$265m

Dec 31 2022US$4mUS$662k

-US$250m

Sep 30 2022n/an/a

-US$231m

Jun 30 2022n/an/a

-US$103m

Mar 31 2022n/an/a

-US$87m

Dec 31 2021US$10mUS$625k

-US$66m

Sep 30 2021n/an/a

-US$34m

Jun 30 2021n/an/a

-US$132m

Mar 31 2021n/an/a

-US$105m

Dec 31 2020US$3mUS$590k

-US$89m

Sep 30 2020n/an/a

-US$90m

Jun 30 2020n/an/a

-US$76m

Mar 31 2020n/an/a

-US$66m

Dec 31 2019US$2mUS$540k

-US$70m

Sep 30 2019n/an/a

-US$73m

Jun 30 2019n/an/a

-US$78m

Mar 31 2019n/an/a

-US$95m

Dec 31 2018US$1mUS$435k

-US$99m

Sep 30 2018n/an/a

-US$107m

Jun 30 2018n/an/a

-US$92m

Mar 31 2018n/an/a

-US$92m

Dec 31 2017US$2mUS$377k

-US$89m

報酬と市場: Ericの 総報酬 ($USD 3.16M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Ericの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Eric Shaff (48 yo)

5.7yrs

在職期間

US$3,158,336

報酬

Mr. Eric D. Shaff, M.B.A., serves as President and Chief Executive Officer at Seres Therapeutics, Inc. since January 15, 2019 and serves as its Director since January 2019. He served as Chief Operating Off...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Eric Shaff
President5.7yrsUS$3.16m0.096%
$ 134.2k
Lisa von Moltke
Executive VP & Chief Medical Officer4.5yrsUS$1.57m0.014%
$ 19.3k
Teresa Young
Executive VP and Chief Commercial & Strategy Officer4.3yrsUS$1.82m0.053%
$ 73.6k
Marella Thorell
Executive VP & CFOless than a yearデータなしデータなし
David Ege
Executive VP & Chief Technology Officer3.9yrsUS$5.32m0.051%
$ 71.3k
Matthew Henn
Executive VP & Chief Scientific Officer5.6yrsUS$1.67m0.044%
$ 61.8k
Carlo Tanzi
Investor Relations Officer8.8yrsデータなしデータなし
Thomas DesRosier
Chief Legal Officer8.3yrsUS$1.44m0.082%
$ 114.1k
Caroline Holda
Assistant General Counselno dataデータなしデータなし

5.0yrs

平均在職期間

57yo

平均年齢

経験豊富な経営陣: MCRBの経営陣は経験豊富で経験豊富です（平均在職期間は5年）。

取締役

名称ポジション在職期間報酬所有権
Eric Shaff
President5.7yrsUS$3.16m0.096%
$ 134.2k
Willard Dere
Independent Director7.2yrsUS$225.23k0.021%
$ 29.2k
Dennis Ausiello
Independent Director9.4yrsUS$222.27k0%
$ 0
Kurt Graves
Independent Director8.8yrsUS$219.23k0%
$ 0
Richard Kender
Independent Director9.9yrsUS$232.69k0.042%
$ 58.3k
Mark Wilcox
Member of Scientific Advisory Board9.7yrsデータなしデータなし
Andrew Goodman
Member of Scientific Advisory Boardno dataデータなしデータなし
Curtis Huttenhower
Member of Scientific Advisory Boardno dataデータなしデータなし
Paul Biondi
Independent Director4.5yrsUS$211.73k0.031%
$ 43.8k
Stephen Berenson
Independent Chairman5.1yrsUS$249.23k0.0024%
$ 3.3k
Robert Jenq
Member of Scientific Advisory Boardno dataデータなしデータなし
Elhanan Borenstein
Member of Scientific Advisory Boardno dataデータなしデータなし

8.0yrs

平均在職期間

63yo

平均年齢

経験豊富なボード: MCRBの 取締役会 は 経験豊富 であると考えられます ( 7.8年の平均在任期間)。